HTG2014-Section-Header-publications

Categories

Filter by Topics

ADCC Gene Alteration adolescents ALK Angiogenesis Apoptosis Autocrine Signaling Biology of neoplasia Biomarkers Bladder Cancer Blood Brain Breast Cancer Cardiovascular Disease CDKN2A mutation Cells Chemokines Circulating miRNAs Colorectal cancer Comparison study Core Needle Biopsy COVID-19 Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Efficacy EMT Epstein-Barr ERBB3 Esophageal Cancer Exosomes extracellular miRNAs Extracellular Vesicles Feasibility FFPE FGF Ligand Trap FGFR Follicular lymphoma Gene Expression Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Head and Neck Cancer Heart HLA-E Homing HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System Immune Cells Immune Checkpoint Inhibitors Immune Response Immune System Immuno-Oncology Immunotherapy Integrins Kidney Liposarcoma Liquid Biopsy Liver liver tissue Lung Lupus Lymphocytes Lymphoma Melanoma Mesothelioma Microenvironment miRNA Molecular Characterization Mouse mRNA custom mTOR signaling Multiple Myeloma MYC Natural Killer Cells Neoantigens Novel Therapeutic Targets Oral Cancer Osteoarthritis Pancreas Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-L1 PFAS PIK3CA mutation Plasma Platform Comparison Programmed cell death protein 1 Prostate Prostate Cancer qNPA qPCR Renal Cell Carcinoma Reproductive Reveal Rheumatoid Arthritis safety Sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Squamous cell carcinoma Sub-typing Therapeutic Response TMB Toxicity TP53 mutation Transplantation Treatment Outcome Treatment Stratification Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes tumor microenvironment Tumor Microenvironment Urine Urothelial carcinoma VEGFR Xenograft Tissue

2021

Gene expression profiling signatures for immunophenotyping of tumor microenvironment using HTG EdgeSeq Precision Immuno-Oncology Panel.

Jaramillo, M. C., et al. Gene expression profiling signatures for immunophenotyping of tumor microenvironment using HTG EdgeSeq Precision Immuno-Oncology Panel. J Clin Oncol 39, 2021 (suppl 15; abstr e14528). DOI: 10.1200/JCO.2021.39.15_suppl.e14528

View External Link

2020

Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma

Xu, J., et al. Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma. J Clin Oncol 38: 2020 (suppl; abstr 3115). 

Download jpg 6.4MB
View External Link

Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC).

Desai, J., et al. Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC). J Clin Oncol 38: 2020 (suppl; abstr e15258). 

View External Link

2019

Association of an Inflammatory Gene Signature with CD8 Expression by Immunohistochemistry (IHC) in Multiple Tumor Types.

Szabo, P. M., et al. Association of an Inflammatory Gene Signature with CD8 Expression by Immunohistochemistry (IHC) in Multiple Tumor Types. Poster session presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019, Chicago, IL.

Download pdf 606KB
View External Link

2018

Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations

Luke J., et al. Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations. Poster session presented at: ESMO 2018 Congress. Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288

View External Link

2017

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Sharma P., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar 18(3):312

PMID: 28131785

View External Link

Page last updated October 21, 2021